


Titre	Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters: a Randomized Controlled Trial
Protocole ID	TRIM-Line 3698
ClinicalTrials.gov ID	NCT05029063
Type(s) de cancer	Contrôle des symptômes
Type étude	Support
Médicament	Rivaroxaban 10 MG
Institution	CISSS DE LA MONTEREGIE-CENTRE  HOPITAL CHARLES-LE MOYNE 3120 boulevard Taschereau, Greenfield Park, QC, J4V2H1
Ville	
Investigateur principal	Dre Catherine Sperlich
Coordonnateur	Caroline Millette 450-466-5000 poste 3276
Statut	Actif en recrutement
Date d'activation	23-03-2023
But étude	The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
Critères d'éligibilité	<ul style="list-style-type: none">• Patients 18 years of age or older with a new or existing diagnosis of cancer and a CVC inserted in the last 72 hours.
Critères d'exclusion	<ul style="list-style-type: none">• CVC in place for >72 hours• Patient requires anticoagulation for other indications• Concomitant use of dual antiplatelet therapy• Major bleeding event in the last 4 weeks• Patients receiving concomitant systemic treatment with strong inhibitors of both CYP 3A4 and P-gp (such as cobicistat, ketoconazole, itraconazole, posaconazole, or ritonavir).• Known pregnancy or plan to become pregnant in next 3 months• Severe renal insufficiency (Creatinine clearance <30 mL/min (defined by Cockcroft-Gault) in the previous 3 months• Documented severe liver disease (e.g., acute clinical hepatitis, chronic active hepatitis or cirrhosis) in the previous 3 months• Known thrombocytopenia (platelet count < 50x 10⁹/L) in the previous 3 months• Known allergy to rivaroxaban• Life expectancy <3 months• History of condition at increased bleeding risk including, but not limited to:<ul style="list-style-type: none">• cerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with recent bleeding, spontaneous or acquired impairment of hemostasis in the past 4 weeks.• Chronic hemorrhagic disorder• Primary malignancy diagnosis of basal cell or squamous cell carcinoma of the skin only• Refused or unable to obtain consent